Your browser is no longer supported. Please, upgrade your browser.
Settings
APRE Aprea Therapeutics, Inc. daily Stock Chart
APRE [NASD]
Aprea Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.86 Insider Own1.40% Shs Outstand18.01M Perf Week20.00%
Market Cap537.60M Forward P/E- EPS next Y-2.01 Insider Trans0.00% Shs Float18.01M Perf Month45.75%
Income-16.60M PEG- EPS next Q-3.94 Inst Own0.20% Short Float0.04% Perf Quarter-
Sales- P/S- EPS this Y-2.20% Inst Trans- Short Ratio0.05 Perf Half Y-
Book/sh-83.99 P/B- EPS next Y30.40% ROA- Target Price26.33 Perf Year-
Cash/sh3.39 P/C8.81 EPS next 5Y- ROE- 52W Range15.10 - 27.87 Perf YTD45.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High7.10% Beta-
Dividend %- Quick Ratio10.90 Sales past 5Y- Gross Margin- 52W Low97.68% ATR2.17
Employees14 Current Ratio10.90 Sales Q/Q- Oper. Margin- RSI (14)- Volatility10.36% 9.88%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.78 Prev Close27.04
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume139.93K Price29.85
Recom2.70 SMA2020.56% SMA5030.31% SMA20030.31% Volume109,638 Change10.39%
Oct-28-19Initiated RBC Capital Mkts Outperform $33
Oct-28-19Initiated Morgan Stanley Equal-Weight $23
Oct-28-19Initiated JP Morgan Neutral $23
Nov-14-19 04:15PM  Aprea Therapeutics Reports Third Quarter 2019 Financial Results GlobeNewswire +10.37%
Nov-11-19 04:40PM  RBC: 3 Stock Picks Set to Soar 30%+ TipRanks
Nov-06-19 09:15AM  Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting GlobeNewswire
Oct-11-19 05:01PM  Gates-Backed Vir Biotechnology Flops in Trading Debut Bloomberg
04:04PM  Insiders Roundup: Facebook, American Defense Systems GuruFocus.com
Oct-08-19 03:59PM  Large Amounts Of Insider Trading In Aprea Therapeutics Following IPO Benzinga -6.47%
Oct-07-19 04:15PM  Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +6.19%
Oct-03-19 11:09AM  Aprea Therapeutics' stock opens 3.1% above IPO price, then rises further MarketWatch
Oct-02-19 11:03PM  Aprea Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire
Sep-30-19 10:21AM  IPO Outlook For The Week: Banks And Biotechs Benzinga
Sep-23-19 08:55AM  Aprea Therapeutics to offer 5 million shares in its IPO, priced at $14 to $16 each MarketWatch
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.